Table 1.
Patient demographics
| Female patients enrolled (n) | 26 |
|---|---|
| Age (years) (median/min/max) | 55.5/32.0/72.0 |
| Mean weight ± SD (kg) (range) | 73.1 ± 14.6 (50-108) |
| Median months from diagnosis of metastatic disease to study entry (months) (range) | 14.4 (1.6-67.2) |
| WHO performance status (n = 26) | |
| 0 | 17 |
| 1 | 9 |
| Steroid hormone receptor status (n = 24) | |
| ER and/or PR+ | 18 |
| ER and PR- | 8 |
| HER2 statusa (n = 22) | |
| HER2+ | 5 |
| HER2- | 17 |
| Metastatic tumor sites (n = 26) | |
| Lung | 17 |
| Bone | 15 |
| Liver | 13 |
| Lymph nodes | 12 |
| Lesions on more than one organ | 22 |
| Race (n = 26) | |
| Caucasian | 20 |
| Asian | 2 |
| Hispanic | 1 |
| African-American | 3 |
aHER2 status confirmed by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC).